Fritextsökning
Artiklar per år
Innehållstyper
-
Anna Törner: The clinical trial – Periscope to reality
What happens to the patients in the clinical trial is not very interesting, writes Anna Törner in a column.
-
The physician at the tech giant: “Observations in the emergency room made my mind up”
When Nasim Farrokhnia was in third grade at school in Tehran, the capital of Iran, her father gave her a book about Marie Curie, which soon became her favourite book. Perhaps her interest in science was born there and then, as science and new technology have since been a constant feature of her working life. Today, she is a Healthcare Manager in Microsoft’s Western Europe team.
-
The first drugs to slow down Alzheimer’s – but what does it mean for patients?
New treatments for early Alzheimer’s are bringing hope to thousands of patients and their families. The question is, who will get the treatment, how will the right patients be found in time, and will the healthcare system’s resources be sufficient? Life Science Sweden has spoken to Swedish researchers in Alzheimer’s who voice cautious hope but also see further challenges.
-
Anna Törner: The minute between life and death
“I have never told anyone about this day that happened more than 20 years ago. But I sometimes reflect on what happened, on what might have happened. When I try to understand why I haven’t told anyone, I find the answer: a feeling of shame. There is no forgiveness for something like this, even though it is very human to be distracted for a moment,” Anna Törner writes in a column.
-
Study: Chat GPT is more empathetic than doctors
The AI tool Chat GPT is not only more accurate when it comes to answering patient questions – the chatbot is also perceived as almost 10 times more empathetic than real doctors, a new study reveals.
-
Column: ”Life as a F1 race”
"The F1 car makes several pit stops during a race and during a lifetime the human being may also have to come in several times for maintenance", Björn Ursing writes in a column.
-
Rapid development in blood analysis – “Sweden is leading the race”
Thousands of analytical tests using just one single drop of blood. What was revealed as a hoax just a few years ago is now a reality, according to KTH professor and serial entrepreneur Mathias Uhlén.
-
Great Swedish innovations: Eye treatment became a feather in Pharmacia’s cap
From complicated and sometimes risky surgery to a routine procedure. Pharmacia’s injectable Healon revolutionised the field of eye surgery - and is considered by us one of the most important contemporary Swedish innovations in the field of medicine.
-
Swedish breakthrough in Alzheimer’s: “We can finally present great data”
Treatments for Alzheimer’s disease are currently among the hottest topics in drug development. Two Swedish research companies with high ambitions and successes in the field participated in Bioscience 2022 conference at Life City in Hagastaden, Stockholm.
-
Cytel Inc acquires the SDS Group
The multinational statistical software developer and contract research organization Cytel Inc, headquartered in Massachusetts, USA, acquires the Swedish consulting company SDS Life Science.
-
“We aim to be a start-up company with an academic spirit”
Chronic pain and Alzheimer’s are two diseases that plague many people worldwide and seem impossible to cure. However, Huddinge-based company Alzecure is working on developing drugs for both conditions.
-
SDS-koncernen köps av amerikanskt bolag
Cytel Inc, med huvudkontor i Massachusetts, USA, förvärvar det svenska konsultbolaget SDS Life Science.
-
The TFS family is growing
TFS HealthScience is a European based CRO company with broad expertise and experiences in the biotech and pharmaceutical sector. The company is growing and the TFS family welcomes new members.
-
Rätt inställd hörapparat kan minska tinnitusbesvär
Enligt en studie från Lunds universitet kan en enkel undersökning och rätt inställning av hörapparater minska tinnitusbesvär.
-
Biosimilars bring price pressure, but are they sufficiently used?
When biosimilars were introduced just over 16 years ago, hopes were raised that they would give many more patients access to effective but otherwise extremely expensive treatments with biological drugs. So, how well has Swedish healthcare used biosimilars? The answer partly depends on whom you ask.
-
Amorphous materials take centre stage when Orexo develops new formulations
Swift resolution but with maintained stability. Orexo’s new drug delivery platform tackles the problem of amorphous materials. “Our technology has the positive properties of the material, and it also cracks some of the problems,” says the company’s Research and Development Manager Robert Rönn.
-
Ny metod för mikroskopi öppnar genväg till nya läkemedel
Forskare vid Chalmers har utvecklat en helt ny mikroskopiteknik för att kunna studera de minsta biologiska partiklarna i sitt naturliga tillstånd – och därmed öppna vägar för snabbare utveckling av nya läkemedel och vaccin.
-
Bakslag för Roche i Alzheimerstudie
Det schweiziska läkemedelsbolaget Roche kunde i resultaten från en preventionsstudie mot Alzheimers sjukdom hos patienter med en genetisk mutation som orsakar tidig utveckling av sjukdomen inte se någon inbromsning eller förhindring av den kognitiva försämringen. Det framgår av ett pressmeddelande.
-
Anna Törner: To kill your darlings
Hopes were high when Anna Törner and her colleague started a study on a dietary supplement that seemed unbelievably good. “Enthusiastically, we dreamed of exciting results and perhaps a publication in a high-impact journal,” she writes in a column.
-
Hello Angelica Loskog!
Life Science Sweden would like to know more about Angelica Loskog and interviews her about her life as a researcher.
-
New rules for diagnostic products, but who will certify them? “An extreme shortage area”
In less than two weeks, new and stricter EU rules will enter into force for thousands of products used in important diagnoses of, among other things, cancer and Covid-19. However, not one single institute in the entire Nordic region is able to certify the diagnostics companies’ products according to the new regulations. “In the end, it risks affecting patients,” says Anna Lefèvre Skjöldebrand, CEO of Swedish Medtech.
-
We will now publish more news in English – and offer yet another newsletter
Starting next week, Life Science Sweden will begin offering a newsletter entirely in English.
-
Miljonstöd till 14 life science-projekt för bättre hälsa
Nya tekniker för fixering av handfrakturer, AI-prediktion av blodtrycksfall och tidig detektion av bukspottkörtelcancer finns bland de 14 projekt för bättre hälsa som får miljonstöd av innovationsprogrammen Swelife och Medtech4health.
-
CAR-T therapies give continued hope: “Almost half of the patients have become disease-free”
become disease-free, at least of those treated with Yescarta, which are the ones I know best,” says Gunilla Enblad, Chairman of the national working group for CAR-T treatment.
BREAKING